Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Hengameh Ahmadi Zare"'
Autor:
Faezeh Maghsood, Mohammad Mehdi Amiri, Amir-Hassan Zarnani, Vahid Salimi, Gholam Ali Kardar, Jalal Khoshnoodi, Maryam Mobini, Hengameh Ahmadi Zare, Abbas Ghaderi, Mahmood Jeddi-Tehrani, Sylvie Schmidt, Géraldine Laumond, Christiane Moog, Fazel Shokri
Publikováno v:
Frontiers in Medicine, Vol 9 (2022)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the outbreak led to the coronavirus disease 2019 (COVID-19) pandemic. Receptor binding domain (RBD) of spike (S) protein of SARS-CoV-2 is considered as a major tar
Externí odkaz:
https://doaj.org/article/eebf607113c546e1b08e74f352bc1c55
Autor:
Mehdi Mohammadi, Mahmood Jeddi-Tehrani, Forough Golsaz-Shirazi, Mohammad Arjmand, Tannaz Bahadori, Mohammad Ali Judaki, Fariba Shiravi, Hengameh Ahmadi Zare, Farzaneh Notash Haghighat, Maryam Mobini, Mohammad Mehdi Amiri, Fazel Shokri
Publikováno v:
Frontiers in Immunology, Vol 11 (2021)
Overexpression of HER2 has been reported in many types of cancer, making it a perfect candidate for targeted immunotherapy. The combination of two FDA approved monoclonal antibodies (mAbs), trastuzumab and pertuzumab, has more robust anti-tumor activ
Externí odkaz:
https://doaj.org/article/3e424d89f2fd4f8d8f3b89a35ab7dbe6
Autor:
Mehdi Mohammadi, Mahmood Jeddi-Tehrani, Forough Golsaz-Shirazi, Mohammad Arjmand, Fatemeh Torkashvand, Tannaz Bahadori, Mohammad Ali Judaki, Fariba Shiravi, Hengameh Ahmadi Zare, Farzaneh Notash Haghighat, Maryam Mobini, Fazel Shokri, Mohammad Mehdi Amiri
Publikováno v:
Journal of Immunotherapy. 46:121-131
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7e869aa0e1fa05cf55f6aa100b871e84
https://doi.org/10.1097/cji.0000000000000464
https://doi.org/10.1097/cji.0000000000000464
Autor:
Danesh Hassani, Mahmood Jeddi-Tehrani, Parisa Yousefi, Samaneh Mansouri-Fard, Maryam Mobini, Hengameh Ahmadi-Zare, Forough Golsaz-Shirazi, Mohammad Mehdi Amiri, Fazel Shokri
Publikováno v:
Cancer chemotherapy and pharmacology. 89(3)
The therapeutic potential of targeting the human epidermal growth factor receptor-3 (ErbB3/HER3) has long been ignored due to impaired tyrosine kinase function and low expression level in tumor cells compared with EGFR and HER2. Although recent inves
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0539003f1271670b93fe75236e4260ef
https://pubmed.ncbi.nlm.nih.gov/35079876
https://pubmed.ncbi.nlm.nih.gov/35079876
Autor:
Farzaneh Notash Haghighat, Mahmood Jeddi-Tehrani, Forough Golsaz-Shirazi, Fazel Shokri, Forough Fatemi, Hengameh Ahmadi Zare, Maryam Mobini, Fariba Shiravi, Mehdi Mohammadi, Mohammad Mehdi Amiri, Tannaz Bahadori, Mohammad Ali Judaki
Publikováno v:
Investigational new drugs. 39(3)
Immunotherapy of HER2-overexpressing cancers by FDA approved monoclonal antibodies (mAbs) such as trastuzumab and pertuzumab has shown promising results. We have recently produced a novel humanized anti-HER2 mAb, hersintuzumab, which did not sterical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03169e39e43c789549f7fef5ce9b5b68
https://pubmed.ncbi.nlm.nih.gov/33389387
https://pubmed.ncbi.nlm.nih.gov/33389387